FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of fecal microbiota transplantation in reducing recurrence of colorectal adenomas after endoscopic resection: study protocol for a multicenter, open-label, randomized, no-treatment-controlled trial. PMID 42045958 · Trials · 2026-Apr-27 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Growth and safety evaluation in very low birth weight infants receiving an exclusive human milk diet: a phase III randomized control trial in Japan. PMID 42045666 · J Perinatol · 2026-Apr-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Inhaled GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. PMID 42045620 · Lung · 2026-Apr-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1-3 prostate cancer. PMID 42044963 · BMJ Open · 2026-Apr-27 This is a protocol for a randomized trial comparing radiotherapy techniques (brachytherapy vs. external beam radiotherapy) with a spacer gel. It is not a drug-containing intervention, is not reported as Phase III, and does not present results with a time-to-event efficacy endpoint. It is a protocol article without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of intraoperative use of 20% albumin in combination with Ringer's lactate versus Ringer's lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial). PMID 42044958 · BMJ Open · 2026-Apr-27 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Conducting a randomized controlled clinical trial on palliative care in patients with glioblastoma - what are the challenges? PMID 42043583 · Support Care Cancer · 2026-Apr-27 The record describes a sub-analysis of the EPCOG trial focusing on trial challenges (screening, attrition, protocol deviations). It is a randomized, human, oncology (glioblastoma) study. However, it is excluded because: 1) The intervention is specialized palliative care (non-drug), not a drug-containing intervention. 2) No time-to-event efficacy endpoint (e.g., OS, PFS) or its analysis (Kaplan-Meier, HR) is reported or signaled in the abstract. 3) The report type is a secondary analysis of trial conduct challenges, not the primary efficacy results of the trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mind the gap: Bayesian equipoise calibration of clinical trial designs. PMID 42037202 · J Biopharm Stat · 2026-Apr-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial. PMID 42061030 · Breast · 2026-Apr-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| How to design a ROCI (Response Over Continuous Intervention) randomised trial: guidance and a case study. PMID 42050422 · BMC Med Res Methodol · 2026-Apr-25 The article is a methodological guide and protocol description for a new trial design (ROCI), using a case study (REFINE-Lung) to illustrate the design. It does not report results of a completed Phase III or II/III randomized trial with a drug intervention and a time-to-event efficacy endpoint. Therefore, it is excluded as a protocol-without-results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Preliminary analysis of mFOLFOXIRI plus bevacizumab combined with cytoreductive surgery for resectable peritoneal metastases from colorectal cancer: a prospective,randomized phase II clinical trial]. PMID 42045712 · Zhonghua Wei Chang Wai Ke Za Zhi · 2026-Apr-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Geriatric Oncology multidomain intervention study to prevent Cognitive impairment among older Indian patients with cancer receiving chemotherapy: a multicentric randomised controlled trial (GOCog). PMID 42034980 · BMC Geriatr · 2026-Apr-25 The record is a protocol for a randomized trial, not a results report. The primary endpoint is cognition (FACT-Cog), not a time-to-event efficacy endpoint. The trial phase is not specified. The intervention is non-drug (exercise + cognitive training), though chemotherapy is part of the standard care context. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of ketogenic diet in glioblastoma: an updated systematic review and meta-analysis. PMID 42032215 · Neurol Sci · 2026-Apr-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials. PMID 42194957 · Genes (Basel) · 2026-Apr-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years - China, 2021-2023. PMID 42170015 · China CDC Wkly · 2026-Apr-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial. PMID 42122978 · J Clin Med · 2026-Apr-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study. PMID 42035994 · Am J Transplant · 2026-Apr-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Continuous Theta-Burst Stimulation on Postoperative Delirium in Older Patients Who Undergo Cardiac Surgery. PMID 42033441 · Neuromodulation · 2026-Apr-24 The study is a randomized trial in humans with a primary result, but it is not oncology, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25). PMID 42033030 · J Natl Cancer Inst · 2026-Apr-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial. PMID 42031476 · BMJ Open · 2026-Apr-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial. PMID 42029635 · Clin Cancer Res · 2026-Apr-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study). PMID 42026662 · Cardiovasc Diabetol Endocrinol Rep · 2026-Apr-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A multicenter, placebo-controlled clinical trial and preliminary experimental study exploring the efficacy of modified Banxia Xiexin Decoction in the treatment of advanced colorectal cancer. PMID 41619866 · J Ethnopharmacol · 2026-Apr-24 The record describes a randomized, placebo-controlled clinical trial in advanced colorectal cancer with time-to-event endpoints (PFS, OS). However, the provided metadata does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information, the eligibility criterion cannot be fully established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Weifuchun inhibits gastric cancer metastasis by inhibiting angiogenesis mediated by the miR-139-5p/CXCR4 axis. PMID 41577154 · J Ethnopharmacol · 2026-Apr-24 The study is a randomized trial with a drug intervention and reports a time-to-event efficacy endpoint (DFS) for gastric cancer. However, the phase of the trial (e.g., Phase III/IIIb or II/III) is not explicitly established in the provided title, abstract, metadata, or deterministic review signals. The deterministic review flagged 'phase3_evidence_unclear'. Therefore, the 'phase3_or_definitive' criterion cannot be confirmed, making the study ineligible under the strict criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial]. PMID 42086522 · Zhonghua Zhong Liu Za Zhi · 2026-Apr-23 The study is an oncology randomized trial with a drug intervention and reports overall survival, but the explicit trial phase is not provided in the metadata or abstract. The primary efficacy endpoint is a continuous measure (hemoglobin change), not a time-to-event endpoint. The time-to-event component (overall survival) is reported as a secondary endpoint with no statistically significant difference, but the absence of a primary/key secondary time-to-event endpoint (like OS or PFS) as the main focus for digitization makes it ineligible for this specific cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. PMID 42019019 · N Engl J Med · 2026-Apr-23 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage. PMID 42019018 · N Engl J Med · 2026-Apr-23 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of a Modular App-Based Pelvic Floor Muscle Training Program for Postoperative Continence Recovery After Radical Prostatectomy: A Multi-Center Randomized Controlled Trial (PELVINTENSE Study). PMID 42122130 · Cancers (Basel) · 2026-Apr-22 The study is an oncology randomized controlled trial reporting primary results, but it evaluates a non-drug intervention (app-based pelvic floor muscle training) and does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary endpoint is continence at 90 days (a binary outcome), not a time-to-event measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026. PMID 42025515 · Eur Urol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-Grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 42025514 · Eur Urol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Hybrid robot-assisted surgery versus conventional fully robotic surgery for colon cancer: study protocol for a multicenter, parallel-group, single-blind randomized controlled superiority trial. PMID 42021265 · BMC Surg · 2026-Apr-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma. PMID 42019971 · J Immunother Cancer · 2026-Apr-22 The study is a randomized Phase III trial in oncology with a drug intervention and reports original results, but it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.) in the provided abstract. The focus is on biomarker and single-cell analysis of treatment response, not clinical survival outcomes. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review. PMID 42018029 · J Neurol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trial. PMID 42017206 · Clin Infect Dis · 2026-Apr-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers. PMID 41384379 · Eur Heart J · 2026-Apr-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Topical Glucocorticosteroids for Proactive Therapy of Acute Radiation-Induced Skin Injury in Head and Neck Cancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. PMID 42072482 · Biomedicines · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Endometriosis-Associated Pain: A Systematic Review and Meta-Analysis. PMID 42025872 · J Minim Invasive Gynecol · 2026-Apr-21 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. PMID 42020286 · Eur Urol Oncol · 2026-Apr-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial. PMID 42020258 · Eur Urol · 2026-Apr-21 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guérin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 42020257 · Eur Urol · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol. PMID 42015297 · Trials · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| NEO-HYPORT: does neoadjuvant radiotherapy improve breast cancer outcomes? An open label, randomised, parallel group, superiority trial to compare the disease-free survival following neoadjuvant versus adjuvant hypofractionated radiotherapy in breast cancer (NEO-HYPORT). PMID 42015277 · Trials · 2026-Apr-21 The record describes a protocol for a randomized trial comparing neoadjuvant vs adjuvant radiotherapy (a non-drug intervention). It is not a report of original trial results with a drug intervention and a primary/key secondary time-to-event efficacy endpoint from a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ProHealth: a co-designed online home-based healthy eating and exercise programme for men with prostate cancer treated with androgen deprivation therapy - a study protocol for a feasibility and preliminary efficacy randomised controlled trial. PMID 42014146 · BMJ Open · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial. PMID 42014145 · BMJ Open · 2026-Apr-21 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Correction: Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial). PMID 42014130 · BMJ · 2026-Apr-21 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early versus deferred immunotherapy in urothelial carcinoma: a review of evidence and post-progression survival. PMID 42012774 · Int Urol Nephrol · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Study protocol, increasing awareness and early detection in students at risk of gynaecological cancer: feasibility of an online educational and behaviour change intervention. PMID 42010640 · Pilot Feasibility Stud · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Gonadotropin-releasing hormone agonist plus aromatase inhibitor versus oral progestins for fertility-sparing treatment in early endometrial carcinoma and atypical hyperplasia: interim analysis of a prospective controlled trial. PMID 42330749 · Int J Gynecol Cancer · 2026-Apr-20 This is an interim report of a prospective randomized controlled trial in oncology (early endometrial carcinoma/atypical hyperplasia) with a drug-containing intervention (GnRH agonist + aromatase inhibitor vs. progestins). However, it is not a Phase III/IIIb or Phase II/III definitive trial (phase is not specified as such, and the interim nature suggests it may be a smaller or earlier-phase study). More critically, the primary endpoint is complete response rate (a binary outcome), not a pre-specified time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or an endpoint reported via Kaplan-Meier/HR). Recurrence rates are mentioned but not as a primary/key secondary time-to-event endpoint with KM/HR. Therefore, it does not meet the core eligibility criteria for a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies. PMID 42074928 · J Clin Med · 2026-Apr-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013. PMID 42010655 · J Hematol Oncol · 2026-Apr-20 Eligibility criteria are met except for the explicit confirmation of a Phase III/IIIb or Phase II/III trial. The study is a randomized trial in human pediatric oncology with drug interventions and time-to-event endpoints (OS, EFS), presenting final comparative results. However, the phase is not explicitly declared in the provided information, and inference is not allowed per adjudication rules. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Reporting of dog-assisted intervention trials: extension of the SPIRIT 2025 and CONSORT 2025 statement. PMID 42010497 · BMC Med Res Methodol · 2026-Apr-20 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |